INTRODUCTION {#s1}
============

The development of intensity-modulated radiation therapy (IMRT) has led to significant improvements in dose conformity; however, this technique increases the time needed for the dose calculation and plan optimization. On the contrary, volumetric modulated arc therapy (VMAT) technique developed by Otto reduces the beam delivery time and inter-fractional error by using fewer monitor units than IMRT \[[@R1]\], moreover, VMAT technique improves the target coverage and reduces systematic error in normal organ \[[@R2]\]. Recent progress made in treatment planning technology has led to improvements in the treatment efficiency, as well as to reduced side effects. However, in the radiation treatment planning process, the final dose-volume histogram (DVH) acquired by IMRT or VMAT differs from the optimal DVH obtained via the optimization process. This is caused by inherent errors in the dose calculation algorithm, such as dose calculation for lateral scatter or buildup region errors due to modeling modulator transmission. This issue arises from optimization convergence error, especially in cases of tissue heterogeneity \[[@R3], [@R4]\].

In recent years, several studies have been conducted on the optimization of convergence error. In one previous study, an improved final DVH was achieved by using the base dose that was acquired from the initial plan to solve the optimization convergence error \[[@R5]\]. Meanwhile, innovative method, named intermediate dose calculation, has been previously applied to the VMAT technique with the jaw tracking option in Progressive resolution optimizer (PRO3) algorithm \[[@R6]\], it was applied to IMRT plans in Eclipse version 11 (Varian Medical Systems, Palo Alto, CA) for the first time in 2009 by Zacarias and Mills \[[@R4]\].

Intermediate dose calculation is carried out during the optimization of the initial plan, after which optimization is continuously performed with the calculated dose distribution; subsequently, the dose calculation algorithm is applied to the treatment plan once more after the optimization is finished. Intermediate dose calculation is essential to ensure an improved and rapid optimization process and target coverage. In addition, for accurately calculating the optimization for heterogeneous materials, Acuros XB (AXB), a specific dose calculation algorithm, was developed \[[@R7]\]. AXB algorithm is similar to classic Monte Carlo method for calculating of dose distribution in heterogeneous material, on the other hand, anisotropic analytical algorithm (AAA) is the dose calculation algorithm base on a pencil beam convolution-superposition method \[[@R8]\]. AAA algorithm in dose calculation improved the weakness of pencil beam convolution algorithm in heterogeneous material. However this algorithm still has the dosimetric error in soft tissue. Whereas, several studies reported that AXB is superior to AAA in inhomogeneous and heterogeneous material \[[@R9]--[@R11]\].

This study aimed to investigate the dosimetric impact of intermediate dose calculation by DVHs, and we moreover briefly examine the dosimetric differences between AAA and AXB algorithms.

RESULTS {#s2}
=======

Phantom study {#s2_1}
-------------

All results derived from the phantom study are summarized in Table [1](#T1){ref-type="table"}. The target coverages investigated with Phantom A showed similar results, and the maximum doses for the target volumes were 102.6%, 101.8%, and 102.6% in Plan1, Plan1-DC, and Plan1-int, respectively. On the other hand, the maximum doses were increased in Phantoms B and C, which included heterogeneous materials. The maximum doses in Phantom B was 99.7%, 101.6%, and 101.8%, respectively, in Plan1, Plan1-DC, and Plan1-int, while the maximum doses in Phantom C were 99.2%, 102.8%, and 103.9%, respectively. As a result, we achieved measurement results with non-negligible differences for the target coverage compared to those in Phantom A.

###### Comparisons of the target coverage in each phantom

                      Plan1   Plan1-DC   Plan1-int
  ----------- ------- ------- ---------- -----------
  Phantom A   CI      1.000   1.000      1.000
  HI          0.030   0.026   0.032      
  UI          1.026   1.023   1.028      
  Phantom B   CI      0.371   1.000      1.000
  HI          0.104   0.039   0.036      
  UI          1.099   1.034   1.031      
  Phantom C   CI      0.318   0.930      0.956
  HI          0.167   0.070   0.076      
  UI          1.165   1.051   1.057      

CI: conformity index, HI: heterogeneity index, UI: uniformity index.

DVH results of the target volume are plotted in Figure [1](#F1){ref-type="fig"}. DVHs of all plans in Phantom A (Figure [1. (a)](#F1){ref-type="fig"}) showed similar results, whereas DVH results for the target volume in Plan1-DC and Plan1-int were significantly improved by using intermediate dose calculation (Figure [1. (b) and (c)](#F1){ref-type="fig"}).

![Dose volume histograms of the target volume in each phantom\
(**a**) Phantom A, (**b**) Phantom B, and (**c**) Phantom C. Dotted line = plan1; solid line = plan1-DC; dot-and-dashed line = plan1-int.](oncotarget-07-37589-g001){#F1}

Clinical cases {#s2_2}
--------------

Figure [2](#F2){ref-type="fig"} shows DVHs of example cases in each treatment region. The dose distributions were calculated by AAA and AXB algorithms. The target coverage was analyzed by DVHs for 30 cancer cases and evaluated by the mean value and standard deviation of CI, HI and UI which are measured on treatment planning system.

![Dose-volume histograms of the target volumes calculated with anisotropic analytic algorithm (AAA) and Acuros XB (AXB) algorithm in Plan1, Plan1-DC, and Plan1-int for head and neck, brain, prostate, and lung cancer cases\
Dotted line = plan1; solid line = plan1-DC; dot-and-dashed line = plan1-int.](oncotarget-07-37589-g002){#F2}

All results calculated by AAA are summarized in Table [2](#T2){ref-type="table"}. As a result, in the case of HN, no clinical difference was found. On the other hand, significant clinical differences were observed for the HI (*p* = 0.043) and UI (*p* = 0.043) between Plan1 and Plan1-int in brain cancer cases, and for HI (*p* = 0.042) between Plan1 and Plan1-DC and UI (*p* = 0.043) between Plan1 and Plan1-int in prostate cancer cases. Table [3](#T3){ref-type="table"} shows the results obtained by AXB. This result showed a similar tendency to those obtained by AAA. In the case of lung cancer, considerable differences in both AAA and AXB algorithms were observed for the target coverage upon intermediate dose calculation, indicating that DVH can be achieved accurately by intermediate dose calculation for the treatment target around heterogeneous material.

###### Summary of each parameter measured by AAA for each region

  AAA             Plan1   Plan1-DC   Plan1-int   *p*-value           
  --------------- ------- ---------- ----------- ----------- ------- -------
  Head and neck                                                      
  CI              Mean    0.833      0.913       0.833       0.221   0.925
  SD              0.221   0.084      0.190                           
  HI              Mean    0.126      0.139       0.108       0.320   0.073
  SD              0.086   0.090      0.085                           
  UI              Mean    1.099      1.117       1.083       0.132   0.147
  SD              0.060   0.073      0.061                           
  Brain                                                              
  CI              Mean    0.981      0.967       0.973       0.715   0.273
  SD              0.017   0.052      0.030                           
  HI              Mean    0.094      0.096       0.077       0.892   0.043
  SD              0.031   0.049      0.023                           
  UI              Mean    1.072      1.077       1.058       0.893   0.043
  SD              0.023   0.042      0.019                           
  Prostate                                                           
  CI              Mean    0.974      1.000       1.000       0.068   0.068
  SD              0.032   0.000      0.000                           
  HI              Mean    0.066      0.043       0.031       0.042   0.043
  SD              0.016   0.005      0.010                           
  UI              Mean    1.053      1.036       1.024       0.043   0.042
  SD              0.016   0.005      0.008                           
  Lung                                                               
  CI              Mean    0.647      0.982       0.961       0.043   0.043
  SD              0.305   0.023      0.036                           
  HI              Mean    0.161      0.088       0.085       0.043   0.043
  SD              0.043   0.023      0.022                           
  UI              Mean    1.140      1.070       1.069       0.043   0.043
  SD              0.052   0.019      0.019                           

AAA: anisotropic analytical algorithm, CI: conformity index, HI: heterogeneity index, UI: uniformity index, SD: standard deviation.

###### Summary of each parameter measured by AXB algorithm for each region

  AXB             Plan1   Plan1-DC   Plan1-int   *p*-value           
  --------------- ------- ---------- ----------- ----------- ------- -------
  Head and neck                                                      
  CI              Mean    0.778      0.923       0.779       0.010   0.826
  SD              0.256   0.071      0.242                           
  HI              Mean    0.125      0.137       0.118       0.443   0.426
  SD              0.075   0.084      0.087                           
  UI              Mean    1.100      1.109       1.095       0.510   0.495
  SD              0.060   0.063      0.067                           
  Brain                                                              
  CI              Mean    0.940      0.978       0.959       0.138   0.138
  SD              0.058   0.033      0.040                           
  HI              Mean    0.092      0.095       0.084       0.715   0.465
  SD              0.025   0.040      0.030                           
  UI              Mean    1.072      1.076       1.063       0.892   0.285
  SD              0.021   0.035      0.024                           
  Prostate                                                           
  CI              Mean    0.975      1.000       0.999       0.043   0.043
  SD              0.026   0.000      0.001                           
  HI              Mean    0.068      0.044       0.034       0.043   0.043
  SD              0.011   0.004      0.008                           
  UI              Mean    1.051      1.035       1.027       0.042   0.043
  SD              0.010   0.004      0.006                           
  Lung                                                               
  CI              Mean    0.546      0.952       0.953       0.043   0.043
  SD              0.294   0.062      0.049                           
  HI              Mean    0.172      0.093       0.089       0.043   0.043
  SD              0.059   0.028      0.026                           
  UI              Mean    1.144      1.077       1.072       0.043   0.043
  SD              0.067   0.025      0.021                           

AXB: Acuros XB, CI: conformity index, HI: heterogeneity index, UI: uniformity index, SD: standard deviation.

The dose maximum values by AAA and AXB algorithms for the target volume are plotted in Figure [3](#F3){ref-type="fig"}. In Plan1-DC, the average maximum values by AAA were 110.4%, 113.3%, 103.4%, and 108.6% in HN, brain, prostate, and lung cancer cases, respectively. The corresponding average maximum values by AXB were 110.7%, 113.0%, 104.8%, and 107.2%, respectively. These results were higher than those for Plan1 and Plan1-int.

![Maximum dose distributions for the target volumes in each region\
Dotted line = plan1; solid line = plan1-DC; dot-and-dashed line = plan1-int. The y-axis shows the dose maximum value (Dmax).](oncotarget-07-37589-g003){#F3}

Figure [4](#F4){ref-type="fig"} shows the target coverage calculated by AAA and AXB algorithms in lung cancer cases. The result revealed that dose distribution by using intermediate dose calculation showed better target coverage in both AAA and AXB algorithms. A comparative study of the dosimetric impact on AAA and AXB algorithms for lung cancer cases are illustrated in Table [4](#T4){ref-type="table"}.

![Comparison of conformity index (CI), heterogeneity index (HI), and uniformity index (UI) in each plan calculated by anisotropic analytic algorithm (AAA) (A, B, C), and Acuros XB (AXB) algorithm (D, E, F) for 5 lung cancer cases\
Dotted line = plan1; solid line = plan1-DC; dot-and-dashed line = plan1-int.](oncotarget-07-37589-g004){#F4}

###### AAA vs. AXB for 5 lung cancer cases

              Target volume   Relative difference (%)   *p*-value   Lung volume   Relative difference (%)   *p*-value
  ----------- --------------- ------------------------- ----------- ------------- ------------------------- -----------
  Plan1       D98%            −2.73                     0.043       V5Gy          1.16                      0.500
  D2%         −1.44           0.043                     V20Gy       −1.64         0.138                     
  Dmean       −1.21           0.042                     MLD         −0.47         0.357                     
  Plan1-DC    D98%            −1.61                     0.080       V5Gy          2.78                      0.043
  D2%         −1.11           0.080                     V20Gy       −0.12         0.893                     
  Dmean       −0.88           0.080                     MLD         0.53          0.257                     
  Plan1-int   D98%            −1.04                     0.080       V5Gy          2.33                      0.225
  D2%         −0.60           0.138                     V20Gy       −0.33         0.686                     
  Dmean       −0.26           0.343                     MLD         −1.24         0.074                     

AAA: anisotropic analytical algorithm, AXB: Acuros XB, D~2/98%~: average dose covering 2% or 98% of the target volume, V~5/20Gy~: average lung volume receiving 5 Gy or 20 Gy, MLD: mean lung dose. Relative difference: (AXB − AAA)/AAA × 100.

A minor relative difference was observed between AAA and AXB algorithms, indicating that the target coverage was lower in AXB plans than in AAA. In Plan1, significant differences between AAA and AXB algorithms for D~98%~, D~2%~, and D~mean~ were observed, whereas these significant differences were reduced between Plan1-DC and Plan1-int. These results were similar to the values observed in the other regions (Table [5](#T5){ref-type="table"}).

###### AAA vs. AXB for head and neck, brain, and prostate cancer cases (Relative difference)

              Target volume   HN      Brain   Prostate
  ----------- --------------- ------- ------- ----------
  Plan1       D~98%~          −1.34   −2.48   −0.60
  D~2%~       −1.67           −2.59   −0.41   
  D~mean~     −1.53           −1.77   −0.74   
  Plan1-DC    D~98%~          −0.96   0.47    −0.27
  D~2%~       −0.87           0.37    −0.21   
  D~mean~     −0.05           0.26    −0.24   
  Plan1-int   D~98%~          −0.60   −1.18   −0.28
  D~2%~       −0.03           −0.37   0.05    
  D~mean~     −0.40           −0.22   −0.18   

AAA: anisotropic analytical algorithm, AXB: Acuros XB algorithm, D~2/98%~: average dose covering 2% or 98% of the target volume, V~5/20Gy~: average lung volume receiving 5 Gy or 20 Gy, MLD: mean lung dose, HN: head and neck. Relative difference = (AXB − AAA)/AAA × 100.

DISCUSSION {#s3}
==========

Treatment plans using IMRT and VMAT techniques are associated with a precise target volume and minimized side effects due to enhanced protection of the normal organ. However, many trials are currently required to achieve an effective treatment plan during the optimization process, and this is associated with a high rate of error.

This study assessed the dosimetric impact of intermediate dose calculation applied to IMRT technique using Eclipse version 11. Our study revealed that intermediate dose calculation is a useful function for IMRT plans. Especially, the target coverage was improved for target volumes using the intermediated calculation method.

In the study by Zacarias and Mills, the final dose distribution was found to be consistent with the result of the repeated optimization process based on the original plan, and the authors therefore concluded that the intermediate dose option is reasonable \[[@R4]\]. Further, Kan et al. reported that there was no difference according to the application of intermediate dose calculation in their phantom study. However, the authors used VMAT technique and evaluated the results according to application of an air cavity correction option simultaneously with the intermediate dose option \[[@R20]\]. Li et al. presented the effect of the intermediate dose calculation for lung cancer cases. They reported that dose homogeneity and optimization efficiency were improved by utilizing the intermediate dose calculation \[[@R21]\].

Various dose calculation algorithm have been developed to ensure accurate dose calculation. Fogliata et al. reported that AXB algorithm can be an alternative to the Monte Carlo calculation \[[@R9]\], and Kan et al. demonstrated that AAA may result in overestimations in small fields \[[@R22]\]. Further, it has been reported that in treatment plans with IMRT or VMAT technique, there is a difference between AAA and AXB algorithms \[[@R23]\].

In the present study, we evaluated the adequacy of intermediate dose calculation for four kinds of treatment regions using IMRT technique. Despite the limited number of clinical cases, this function was found to be effective in obtaining an accurate final DVH. Finally, this study also proposed which dose calculation algorithm should be considered for obtaining a better dose distribution for heterogeneous media through analysis between AAA and AXB algorithms with intermediate dose calculation.

CONCLUSIONS {#s4}
===========

This study analyzed DVHs according to the application of intermediate dose calculation. In conclusion, we found that intermediate dose calculation in IMRT plans improved the target coverage in target volumes surrounded by heterogeneous materials such as target volume in prostate and lung cancer cases. Moreover, the optimization time can be reduced during the optimization process. Therefore, it seems reasonable to conclude that intermediate dose calculation should be applied to IMRT plans. However, the full impact of optimization convergence error remains to be investigated. In the comparison of the differences in dose distribution between AAA and AXB algorithms, our results suggest that the dose calculation should be considered by using the developed AXB algorithm.

MATERIALS AND METHODS {#s5}
=====================

Phantom study {#s5_1}
-------------

It is necessary to evaluate the dosimetric impact of intermediate dose calculation with a phantom. First, we created three kinds of virtual water phantoms in the treatment planning system: Phantoms A, B, and C. The target volume was created with a diameter of 2 cm in homogeneous Phantom A. An air cavity, with a diameter of 4 cm, was formed in Phantom B, with the diameter of the target volume in Phantom B being the same as that of Phantom A, but including part of the air cavity. In Phantom C, the target volume was delineated with a diameter of 2 cm in the center, and a ring with a width of 2 cm was filled around the target volume (Figure [5](#F5){ref-type="fig"}). A treatment plan using 6 MV photons with 9 fields was generated for each phantom, and the fields were equally spaced at 40° intervals. IMRT technique was applied to all plans, and dose calculation was performed by AAA.

![Axial views of the central slice for (a) Phantom A (homogeneous material), (b) Phantom B (small air cavity), and (c) Phantom C (air cavity around the target)](oncotarget-07-37589-g005){#F5}

To analyze the dosimetric impact of the intermediate dose calculation, three kinds of treatment plans were established for each phantom. The first plan was created by optimization and dose calculation without intermediate dose calculation (Plan1). The second plan was generated by re-optimizing and re-calculating Plan1 (Plan1-DC). The dose distribution of Plan1 was used as the intermediate dose at this time. The third plan was produced by optimization and dose calculation with intermediate dose calculation from the beginning (Plan1-int).

The target volume coverage was evaluated by the conformity, heterogeneity, and uniformity, using DVHs in Eclipse. Conformity index (CI), heterogeneity index (HI), and uniformity index (UI) were defined as follows \[[@R12]\]: $$\textit{CI} = \frac{TV_{95\%}}{\textit{TV}},$$ where TV is the target volume and TV~95%~ is the volume covered by 95% of the prescribed dose; $$\textit{HI} = \frac{D_{2\%} - D_{98\%}}{D_{50\%}},$$ where D~2%~ is the dose of 2% of the target volume, D~98%~ is the dose of 98% of the target volume, and D~50%~ is the dose of 50% of the target volume \[[@R13]\]; and $$\textit{UI} = \frac{D_{5\%}}{D_{95\%}},$$ where D~5%~ is the dose of 5% of the target volume, and D~95%~ is the dose of 95% of the target volume \[[@R14]\].

Clinical cases {#s5_2}
--------------

In head and neck (HN) and brain cancer cases, the treatment target volume is complex, and critical normal organs such as the parotid grand, optic apparatus, and spinal cord are adjacent to the target volume. Therefore, a sharp dose response curve and precise dose calculation are required. In a previous study, IMRT technique showed excellent results for these cases in comparison with three-dimensional conformal radiation therapy \[[@R15], [@R16]\]. In addition, IMRT technique has also been applied to the treatment plan in order to improve the treatment toxicity and the disease-free survival in prostate cancer cases \[[@R17], [@R18]\], while, in lung cancer cases, side effects such as pneumonia can be reduced by protecting the healthy lung, esophagus, heart, and spinal cord using this technique \[[@R19]\]. Thus, using IMRT technique in the treatment plan can also improve the dose escalation for these treatment regions.

In this study, CT scans of 30 patients were randomly chosen to assess the dosimetric impact of intermediate dose calculation. The treatment regions of these patients were in the HN (*n* = 15), brain (*n* = 5), prostate (*n* = 5), and lung (*n* = 5). The images were obtained with 2.5 mm slice thickness from 3D-computed tomography (GE Health-care, Buckinghamshire, UK). Three kinds of treatment plans were generated for each image, similar to in the phantom study. The same constraints and priorities in the optimization process were applied to the set of plans (Plan1, Plan1-DC, and Plan1-int). Dose calculation of these treatment plans was carried out by AAA and AXB algorithms.

To evaluate the dosimetric impact of intermediate dose calculation, the target coverage for IMRT plans was estimated by CI, HI, and UI through DVH. The dose distribution by AAA was compared with that by AXB for each treatment region. For the statistical analyses, the Statistical Program for Social Sciences (SPSS version 18; SPSS Inc., Chicago, IL) was used.
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